Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma-Reference-Cited by-同舟云学术

Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma

Published:2022-06-23 Issue:8 Volume:28 Page:1599-1611
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Zhu Andrew X.,Abbas Alexander R.,de Galarreta Marina Ruiz^ORCID,Guan Yinghui,Lu Shan,Koeppen Hartmut,Zhang Wenjun,Hsu Chih-Hung,He Aiwu Ruth,Ryoo Baek-Yeol,Yau Thomas,Kaseb Ahmed O.,Burgoyne Adam M.,Dayyani Farshid^ORCID,Spahn Jessica,Verret Wendy,Finn Richard S.,Toh Han Chong,Lujambio Amaia^ORCID,Wang Yulei^ORCID

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

https://www.nature.com/articles/s41591-022-01868-2.pdf

Reference57 articles.

1. Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209–249 (2021).

2. Lee, M. S. et al. GO30140 Investigators. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study. Lancet Oncol. 21, 808–820 (2020).

3. Finn, R. S. et al. IMbrave150 Investigators. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N. Engl. J. Med. 382, 1894–1905 (2020).

4. Socinski, M. A. et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N. Engl. J. Med. 378, 2288–2301 (2018).

5. McDermott, D. F. et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat. Med. 24, 749–757 (2018).

Cited by 270 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cucurbitacin I exerts its anticancer effects by inducing cell cycle arrest via the KAT2a-ube2C/E2F1 pathway and inhibiting HepG2-induced macrophage M2 polarization;Biochemical and Biophysical Research Communications;2024-12

2. Antitumor effects of IOX1 combined with bevacizumab-induced apoptosis and immunity on colorectal cancer cells;International Immunopharmacology;2024-11

3. IL-6/STAT3 signaling pathway induces prostate apoptosis response protein-4(PAR-4) to stimulate malignant behaviors of hepatocellular carcinoma cells;Annals of Hepatology;2024-11

4. Biohybrid hydrogel inhibiting β-klotho/HDAC3 axis for hepatocellular carcinoma treatment;International Journal of Biological Macromolecules;2024-10

5. Immunotherapy for hepatocellular carcinoma;JHEP Reports;2024-10